Medical Devices Aren’t Luxury Goods, So Why Does Medtech Try To Sell Them That Way?
Clinical outcomes, quality and total cost of care are driving hospital purchasing decisions more than ever before. Providers can no longer justify spending on medical devices as clinical luxuries without links to outcomes. ZS recommends five fundamental factors that medtech needs to successfully communicate outcomes-based value.
You may also be interested in...
Becton Dickinson has reached a definitive agreement to acquire CR Bard for $24bn. BD says Bard's product portfolio gives it a strong presence in fast-growing clinical areas and more reach outside the US while Bard expects to reach more customers by building on BD's leadership in medication management and infection prevention.
Federal health-care policy in the US, at least, is potentially in for a major transition, but that is not having much of an impact on the fundamental business models of medtech firms and their ever-accelerating focus on value-based and risk-sharing business models. Emphasis on value strategies was a significant medtech theme at this year's JP Morgan Healthcare Conference bonanza.
US hospitals have suddenly started to care economically about the episodes of care that patients receive – an adjustment that requires medtech companies to adapt accordingly. So says ZS Associates in a new report about how companies need to work in step with providers as the transition to outcomes-based care accelerates.